Where is Adnexus located?

Adnexus is headquartered in Dallas, United States.

Is Adnexus a funded company?

Adnexus is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Adnexus rank among its competitors?

Adnexus ranks 2680th amongst 2826 active competitors, of which 947 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Adnexus?

Adnexus' top competitors include Jazz Pharmaceuticals, Alexion and Sana Biotechnology. Among them, Karyopharm secured the most recent funding round in March, 2026.

Adnexus - 2026 Company Profile & Competitors

Company Details

Developer of proteins and monoclonal antibodies for the treatment of infectious diseases. It offers AI-based platform that identify conserved and immutable targets for producing antibodies that target specific sites on viruses.

Website: www.adnexusbiotech.com/
Social
Email ID: *****@adnexus.com

Key Metrics

Founded Year

2024

Location

Dallas, United States

Stage

Unfunded

Ranked

2680^th among 2826 active competitors

Similar Companies

Alexion & 584 more

View Adnexus' full profile

Adnexus has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adnexus include Jazz Pharmaceuticals, Alexion and Sana Biotechnology. Here is the list of Top 10 competitors of Adnexus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2680th	Adnexus 2024, Dallas (United States), Unfunded	Developer of proteins and monoclonal antibodies for the treatment of infectious diseases	-	-	20/100